Yıl: 2022 Cilt: 31 Sayı: 2 Sayfa Aralığı: 116 - 126 Metin Dili: İngilizce DOI: 10.5152/turkjnephrol.2022.21133 İndeks Tarihi: 06-07-2022

Main Outcomes of the DIYAL-TR Study: Regional Differences of Mortality and Morbidity in Chronic Hemodialysis Patients

Öz:
Objective: Variations in care at national or global level may have an impact on the prognosis of patients on chronic hemodialysis. We aimed to describe regional differences in all-cause mortality or cardiovascular morbidity in chronic hemodialysis patients in Turkey. Methods: We enrolled 2461 patients who were initiated chronic hemodialysis in 93 centers in Turkey between January 27, 2017, and February 09, 2018. We included 2-year follow-up data of 1877 patients in this prospective study. The primary outcome, the rate of composite endpoint of all-cause mortality or cardiovascular morbidity, was compared between geographical regions. Secondary outcomes were the rates of hospitalization and infections. Results: In total, 552 patients (29.4%) developed the primary outcome. The highest and lowest rates of primary outcome occurred in the Mediterranean (34.5%) and Southeastern (26.5%) & Central Anatolian regions (26.5%), respectively, with no significant differences across regions (P = .82). Hospitalization events were detected in 377 patients (20.1%). The highest rate of hospitalization was detected in the Black Sea region (33.8%), and the lowest (7.6%) in the Southeastern region. The regions did not differ in hospitalization rates (P = .88). Infections occurred in 11.3% (n = 212) of the patients. The highest and lowest rates of infections occurred in the Aegean (18.2%) and the Southeastern (2.9%) regions, respectively. We detected significant difference between geographic regions (P = .02). Conclusions: Our study showed that almost 3 in every 10 chronic hemodialysis patients reached the primary endpoint of all-cause mortality/cardiovascular morbidity during the 2 years of follow-up. The occurrence of this outcome does not seem to exhibit geographical variation across the country.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395(10225):709-733. [CrossRef]
  • 2. Suleymanlar G, Ateş K, Seyahi N. Registry of the Nephrology, Dialysis and Transplantation in Turkey. Registry 2019. Ankara: The Turkish Society of Nephrology; 2020.
  • 3. Cockwell P, Fisher LA. The global burden of chronic kidney disease. Lancet. 2020;395(10225):662-664. [CrossRef]
  • 4. Young EW, Goodkin DA, Mapes DL, et al. The Dialysis Outcomes and Practice Patterns Study (DOPPS): an international hemodialysis study. Kidney Int. 2000;57(Suppl):S74-S81. [CrossRef]
  • 5. Goodkin DA, Young EW, Kurokawa K, Prütz KG, Levin NW. Mortality among hemodialysis patients in Europe, Japan, and the United States: case-mix effects. Am J Kidney Dis. 2004;44(5)(Suppl 2):16- 21. [CrossRef]
  • 6. Goodkin DA, Bragg-Gresham JL, Koenig KG, et al. Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol. 2003;14(12):3270-3277. [CrossRef]
  • 7. Davison SN, Jhangri GS, Johnson JA. Cross-sectional validity of a modified Edmonton symptom assessment system in dialysis patients: a simple assessment of symptom burden. Kidney Int. 2006;69(9):1621-1625. [CrossRef]
  • 8. Evans RW, Manninen DL, Garrison LP, Jr, et al. The quality of life of patients with endstage renal disease. N Engl J Med. 1985;312(9):553- 559. [CrossRef]
  • 9. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15(8):2208- 2218. [CrossRef]
  • 10. Mapes DL, Lopes AA, Satayathum S, et al. Health-related quality of life as a predictor of mortality and hospitalization: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Kidney Int. 2003;64(1):339-349. [CrossRef]
  • 11. Lopes AA, Bragg J, Young A, et al. Depression as a predictor of mortality and hospitalization among hemodialysis patients in the United States and in Europe in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Kidney Int. 2002;61:199-207.
  • 12. DİADER 2014 Diyaliz İstatistik Yıllığı; 2015. https://www.diader.org. tr/index.php/istatislikler/item/1148-istatistik-yilligi-2015
  • 13. Utaş C, Arik N, Ates K, Ecder T, Sifil A. Türkiye’de farklı Coğrafi Bölgeler arasındaki Hemodiyaliz hasta profili ve Parametreleri Farklılıkları [Differences in hemodialysis patient profiles and parameters between geographic regions of Turkey]. Turk Neph Dial Transpl. 2015;283(3)(Suppl 1):24.
  • 14. Kızılırmak P, Ecder T, Ateş K, et al. Diyal-TR registry: investigation of clinical characteristics of the patients under chronic hemodialysis therapy in Turkey. Turk Klin J Intern Med. 2020;5(1):1-7.
  • 15. United States Renal Data System. 2018 USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases.
  • 16. Luxardo R, Kramer A, González-Bedat MC, et al. The epidemiology of renal replacement therapy in two different parts of the world: the Latin American Dialysis and Transplant Registry versus the European Renal Association-European Dialysis and Transplant Association Registry. Rev Panam Salud Publica. 2018;42:e87. [CrossRef]
  • 17. Ecder T, Utas C, Ates K, et al. The Dialysis Outcomes and Practice Patterns Study (DOPPS) in Turkey. Hemodial Int. 2017;21(3):430- 439. [CrossRef]
  • 18. TSN Renal Registry Committee. Turkish Society of Nephrology 2017 Turkish Renal Registry Report; 2017. Ankara; 2018. ISBN 978-605-62465-0-0.
  • 19. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. The impact of anemia on cardiomyopathy, morbidity, and and mortality in end-stage renal disease. Am J Kidney Dis. 1996;28(1):53- 61. [CrossRef]
  • 20. Regidor DL, Kopple JD, Kovesdy CP, et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol. 2006;17(4):1181-1191. [CrossRef]
  • 21. Hanafusa N, Nomura T, Hasegawa T, Nangaku M. Age and Anemia Management: relationship of hemoglobin levels with mortality might differ between elderly and nonelderly hemodialysis patients. Nephrol Dial Transplant. 2014;29(12):2316-2326. [CrossRef]
  • 22. Levy AR, Xing S, Brunelli SM, et al. Symptoms of secondary hyperparathyroidism in patients receiving maintenance hemodialysis: a prospective cohort study. Am J Kidney Dis. 2020;75(3):373-383. [CrossRef]
  • 23. Rodríguez-Ortiz ME, Rodríguez M. Recent advances in understanding and managing secondary hyperparathyroidism in chronic kidney disease. F1000Research. 2020;9:F1000 Faculty Rev-1077. [CrossRef]
  • 24. General Directorate of Health Information Systems, Ministry of Health of Turkey. Health Statistics Yearbook 2019. Ankara; 2021. ISBN 978-975-590-793-2 Ministry of Health Publication No: 1186.
  • 25. Sahin A, Akici A, Aydin V, Melik B, Aksoy M, Alkan A. Variation of antibiotic consumption and its correlated factors in Turkey. Eur J Clin Pharmacol. 2017;73(7):867-873. [CrossRef]
  • 26. Aslam N, Bernardini J, Fried L, Burr R, Piraino B. Comparison of infectious complications between incident hemodialysis and peritoneal dialysis patients. Clin J Am Soc Nephrol. 2006;1(6):1226- 1233. [CrossRef]
  • 27. Dalrymple LS, Go AS. Epidemiology of acute infections among patients with chronic kidney disease. Clin J Am Soc Nephrol. 2008;3(5):1487-1493. [CrossRef]
  • 28. Allon M, Depner TA, Radeva M, et al. Impact of dialysis dose and membrane on infection-related hospitalization and death: results of the HEMO Study. J Am Soc Nephrol. 2003;14(7):1863-1870. [CrossRef]
APA Kızılırmak P, Ecder T, Ateş K, ARICI M, SEZER S, Kaptanoğulları H, ARINSOY T (2022). Main Outcomes of the DIYAL-TR Study: Regional Differences of Mortality and Morbidity in Chronic Hemodialysis Patients. , 116 - 126. 10.5152/turkjnephrol.2022.21133
Chicago Kızılırmak Pınar,Ecder Tevfik,Ateş Kenan,ARICI Mustafa,SEZER SİREN,Kaptanoğulları Hakan,ARINSOY TURGAY Main Outcomes of the DIYAL-TR Study: Regional Differences of Mortality and Morbidity in Chronic Hemodialysis Patients. (2022): 116 - 126. 10.5152/turkjnephrol.2022.21133
MLA Kızılırmak Pınar,Ecder Tevfik,Ateş Kenan,ARICI Mustafa,SEZER SİREN,Kaptanoğulları Hakan,ARINSOY TURGAY Main Outcomes of the DIYAL-TR Study: Regional Differences of Mortality and Morbidity in Chronic Hemodialysis Patients. , 2022, ss.116 - 126. 10.5152/turkjnephrol.2022.21133
AMA Kızılırmak P,Ecder T,Ateş K,ARICI M,SEZER S,Kaptanoğulları H,ARINSOY T Main Outcomes of the DIYAL-TR Study: Regional Differences of Mortality and Morbidity in Chronic Hemodialysis Patients. . 2022; 116 - 126. 10.5152/turkjnephrol.2022.21133
Vancouver Kızılırmak P,Ecder T,Ateş K,ARICI M,SEZER S,Kaptanoğulları H,ARINSOY T Main Outcomes of the DIYAL-TR Study: Regional Differences of Mortality and Morbidity in Chronic Hemodialysis Patients. . 2022; 116 - 126. 10.5152/turkjnephrol.2022.21133
IEEE Kızılırmak P,Ecder T,Ateş K,ARICI M,SEZER S,Kaptanoğulları H,ARINSOY T "Main Outcomes of the DIYAL-TR Study: Regional Differences of Mortality and Morbidity in Chronic Hemodialysis Patients." , ss.116 - 126, 2022. 10.5152/turkjnephrol.2022.21133
ISNAD Kızılırmak, Pınar vd. "Main Outcomes of the DIYAL-TR Study: Regional Differences of Mortality and Morbidity in Chronic Hemodialysis Patients". (2022), 116-126. https://doi.org/10.5152/turkjnephrol.2022.21133
APA Kızılırmak P, Ecder T, Ateş K, ARICI M, SEZER S, Kaptanoğulları H, ARINSOY T (2022). Main Outcomes of the DIYAL-TR Study: Regional Differences of Mortality and Morbidity in Chronic Hemodialysis Patients. Turkish journal of nephrology (Online), 31(2), 116 - 126. 10.5152/turkjnephrol.2022.21133
Chicago Kızılırmak Pınar,Ecder Tevfik,Ateş Kenan,ARICI Mustafa,SEZER SİREN,Kaptanoğulları Hakan,ARINSOY TURGAY Main Outcomes of the DIYAL-TR Study: Regional Differences of Mortality and Morbidity in Chronic Hemodialysis Patients. Turkish journal of nephrology (Online) 31, no.2 (2022): 116 - 126. 10.5152/turkjnephrol.2022.21133
MLA Kızılırmak Pınar,Ecder Tevfik,Ateş Kenan,ARICI Mustafa,SEZER SİREN,Kaptanoğulları Hakan,ARINSOY TURGAY Main Outcomes of the DIYAL-TR Study: Regional Differences of Mortality and Morbidity in Chronic Hemodialysis Patients. Turkish journal of nephrology (Online), vol.31, no.2, 2022, ss.116 - 126. 10.5152/turkjnephrol.2022.21133
AMA Kızılırmak P,Ecder T,Ateş K,ARICI M,SEZER S,Kaptanoğulları H,ARINSOY T Main Outcomes of the DIYAL-TR Study: Regional Differences of Mortality and Morbidity in Chronic Hemodialysis Patients. Turkish journal of nephrology (Online). 2022; 31(2): 116 - 126. 10.5152/turkjnephrol.2022.21133
Vancouver Kızılırmak P,Ecder T,Ateş K,ARICI M,SEZER S,Kaptanoğulları H,ARINSOY T Main Outcomes of the DIYAL-TR Study: Regional Differences of Mortality and Morbidity in Chronic Hemodialysis Patients. Turkish journal of nephrology (Online). 2022; 31(2): 116 - 126. 10.5152/turkjnephrol.2022.21133
IEEE Kızılırmak P,Ecder T,Ateş K,ARICI M,SEZER S,Kaptanoğulları H,ARINSOY T "Main Outcomes of the DIYAL-TR Study: Regional Differences of Mortality and Morbidity in Chronic Hemodialysis Patients." Turkish journal of nephrology (Online), 31, ss.116 - 126, 2022. 10.5152/turkjnephrol.2022.21133
ISNAD Kızılırmak, Pınar vd. "Main Outcomes of the DIYAL-TR Study: Regional Differences of Mortality and Morbidity in Chronic Hemodialysis Patients". Turkish journal of nephrology (Online) 31/2 (2022), 116-126. https://doi.org/10.5152/turkjnephrol.2022.21133